Telix Pharmaceuticals Limited (TLX)
(Delayed Data from NSDQ)
$10.93 USD
+0.88 (8.76%)
Updated Sep 23, 2025 04:00 PM ET
After-Market: $10.92 -0.01 (-0.09%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth F Momentum D VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
TLX 10.93 +0.88(8.76%)
Will TLX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for TLX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TLX
All You Need to Know About Telix Pharmaceuticals Limited (TLX) Rating Upgrade to Buy
Telix Shares May Gain on the Distribution Deal With Cardinal Health
TLX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Telix Pharmaceuticals Limited (TLX) Upgraded to Buy: What Does It Mean for the Stock?
What Makes Telix Pharmaceuticals Limited (TLX) a Good Fit for 'Trend Investing'
Other News for TLX
UBS Maintains Buy Rating on TLX, Lowers Target Price to $20 | TLX Stock News
Telix Pharmaceuticals price target lowered by $3 at UBS
Is TLX signaling a buying opportunity? Crossed Above 20 Day Moving Average shows up after rising 0.7%
UBS Sticks to Its Buy Rating for Telix Pharmaceuticals (TLPPF)
Telix Pharmaceuticals (TLPPF) Receives a Buy from Morgan Stanley